Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical develops medicines for rare genetic diseases that affect a small number of people and are often overlooked by larger pharmaceutical companies. The company has four approved drugs on the market, including Crysvita for a bone disease caused by high phosphate levels, Mepsevii for a storage disease that affects children, Dojolvi for a fatty acid disorder, and Evkeeza for high cholesterol. It also has several experimental treatments in late-stage testing, including gene therapies that aim to fix the underlying genetic problems causing diseases like Sanfilippo syndrome and…